About Paul Kleutghen
Articles by Paul Kleutghen
Updated Teclistamab Results in Multiple MyelomaJun 17, 2022
Long Wait Times Limit Access to CAR-T Treatment in MyelomaJun 12, 2022
Managing Neurotoxicity Events in Myeloma Patients Treated with the CARVYKTI CAR TJun 12, 2022
Body Mass Index Associated with the Progression of MGUSMay 09, 2022
Ninlaro Outcomes as a Replacement for Velcade or Kyprolis Following a Myeloma RelapseApr 28, 2022
Iberdomide un nuevo y potente fármaco para tratar el mielomaApr 26, 2022
Velcade and Green Tea: A Myeloma No-NoApr 10, 2022
Generic Revlimid in Myeloma: Don't Get Too ExcitedApr 10, 2022
CAR-T Constructs and the Potential Future Promise of OX40-CAR-T in Multiple MyelomaApr 06, 2022
El efecto positivo de la terapia de consolidación en el mieloma múltipleMar 21, 2022
What is Important to Myeloma Patients? Progression Free Survival, Overall Survival or MRD Negative Status?Mar 21, 2022
Plasma Cell Leukemia Case ReportsMar 21, 2022
Melflufen Update: A Modern Myeloma SagaMar 16, 2022
FDA grants Fast Track Review to Tri-Specific Antibody HPN217 to treat Relapsed/Refractory MyelomaMar 15, 2022
Unraveling a Multiple Myeloma Mystery by Studying Bone LesionsFeb 18, 2022
Motixafortide: A New Drug to Mobilize Stem Cells Prior to Stem Cell TransplantJan 21, 2022
Early Indicators for Depth of Response Rates in Myeloma Patients Treated with BCMA CAR T CellsJan 06, 2022
A Potential Warning Sign for Allo CAR T in Multiple MyelomaNov 24, 2021
CAR T Treatment and Infection Risk in the Age of SARS Cov-2Nov 18, 2021
FDA Approval for Shingrix to Prevent Shingles in AMLAug 13, 2021
FDA Approval for Shingrix to Prevent Shingles Post Auto Stem Cell Transplant Transplant in Multiple MyelomaAug 09, 2021
Use of Beta-Blockers Improves Outcomes for Myeloma Patients on PomalystJul 23, 2021
Iberdomide: A Potent New Drug to Treat Revlimid/Pomalyst Resistant MyelomaJul 07, 2021
A Skin Patch Administration of Lenalidomide in Multiple Myeloma?Jul 01, 2021
